Biotech Acquisition (BIOT) and Blade Report Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat May 18, 2022 09:02AM
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference May 18, 2022 09:01AM
Blade Therapeutics (BIOT) Reports Data from Phase 1 and Preclinical Studies of Cudetaxestat May 16, 2022 09:02AM
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference May 16, 2022 09:01AM
Biotech Acquisition (BIOT) and Blade Therapeutics Announce Effectiveness of Registration Statement, Signs $75M Committed Equity Financing May 10, 2022 05:40AM


May 9, 2022 06:10PM Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combinat
Apr 4, 2022 03:51PM Biotech Acquisition (BIOT) Files Amended S4 for Proposed Merger with Blade Therapeutics
Apr 4, 2022 03:49PM Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
Apr 4, 2022 08:00AM Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
Mar 24, 2022 08:00AM Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
Mar 16, 2022 08:00AM Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
Mar 7, 2022 08:00AM Blade Therapeutics to Participate in Upcoming Investor Conferences
Nov 8, 2021 08:01AM Biotech Acquisition (BIOT) and Blade Therapeutics Announce Definitive Merger Agreement
Nov 8, 2021 08:00AM Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement